-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
Bristol-Myers Squibb (BMS) and 2seventy bio today jointly announced that their chimeric antigen receptor (CAR) T-cell therapy Abecma (idecabtagene viccleucel) is in the treatment of KarMMa-3 in patients with relapsed or refractory multiple myeloma (RRMM).Multiple myeloma is a still incurable cancer of blood cells that primarily affects cells in the bone marrow called plasma cells
[1] Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress